Mallett Andrew, Patel Chirag, Maier Barbara, McGaughran Julie, Gabbett Michael, Takasato Minoru, Cameron Anne, Trnka Peter, Alexander Stephen I, Rangan Gopala, Tchan Michel C, Caruana Georgina, John George, Quinlan Cathy, McCarthy Hugh J, Hyland Valentine, Hoy Wendy E, Wolvetang Ernst, Taft Ryan, Simons Cas, Healy Helen, Little Melissa
Kidney Health Service and Conjoint Kidney Research Laboratory, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Centre for Kidney Disease Research, Centre for Chronic Disease and CKD.QLD, School of Medicine, The University of Queensland, St Lucia, Australia.
BMC Nephrol. 2015 Sep 15;16:152. doi: 10.1186/s12882-015-0148-8.
Genetic renal diseases (GRD) are a heterogeneous and incompletely understood group of disorders accounting for approximately 10 % of those diagnosed with kidney disease. The advent of Next Generation sequencing and new approaches to disease modelling may allow the identification and validation of novel genetic variants in patients with previously incompletely explained or understood GRD.
METHODS/DESIGN: This study will recruit participants in families/trios from a multidisciplinary sub-specialty Renal Genetics Clinic where known genetic causes of GRD have been excluded or where genetic testing is not available. After informed patient consent, whole exome and/or genome sequencing will be performed with bioinformatics analysis undertaken using a customised variant assessment tool. A rigorous process for participant data management will be undertaken. Novel genetic findings will be validated using patient-derived induced pluripotent stem cells via differentiation to renal and relevant extra-renal tissue phenotypes in vitro. A process for managing the risk of incidental findings and the return of study results to participants has been developed.
This investigator-initiated approach brings together experts in nephrology, clinical and molecular genetics, pathology and developmental biology to discover and validate novel genetic causes for patients in Australia affected by GRD without a known genetic aetiology or pathobiology.
遗传性肾病(GRD)是一组异质性且尚未完全了解的疾病,约占确诊肾病患者的10%。新一代测序技术的出现以及疾病建模的新方法,可能有助于识别和验证先前病因未完全解释或理解的GRD患者中的新基因变异。
方法/设计:本研究将从多学科肾脏遗传学专科门诊招募家庭/三联体参与者,这些门诊已排除已知的GRD遗传病因或无法进行基因检测。在患者知情同意后,将进行全外显子组和/或基因组测序,并使用定制的变异评估工具进行生物信息学分析。将对参与者数据管理采取严格流程。通过将患者来源的诱导多能干细胞体外分化为肾脏及相关肾外组织表型,对新的基因发现进行验证。已制定了管理偶发发现风险及向参与者反馈研究结果的流程。
这种由研究者发起的方法汇聚了肾脏病学、临床和分子遗传学、病理学及发育生物学领域的专家,旨在为澳大利亚患有GRD但无已知遗传病因或病理生物学的患者发现并验证新的遗传病因。